The four board members who voted Arcturus Therapeutics Inc. founder Joseph Payne out of the RNA drug development firm at the end of January have been replaced under a settlement between the executive and the company announced May 29. And now, as of May 31, Payne has been reinstated as president and CEO, four months after he was unexpectedly fired.
Payne, who is Arcturus' largest shareholder with a 13.7% stake in the San Diego-based company, has demanded since the beginning of February that its board of directors call an extraordinary general meeting (EGM) of shareholders to vote on the replacement of four board members with four nominees of his own
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?